Financiere des Professionnels Fonds d investissement inc. Has $9.15 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Financiere des Professionnels Fonds d investissement inc. trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 8.2% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 18,380 shares of the medical research company's stock after selling 1,638 shares during the quarter. Financiere des Professionnels Fonds d investissement inc.'s holdings in Thermo Fisher Scientific were worth $9,146,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Bernard Wealth Management Corp. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $25,000. Pillar Financial Advisors LLC acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $29,000. Ameriflex Group Inc. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $30,000. Cassady Schiller Wealth Management LLC boosted its stake in Thermo Fisher Scientific by 89.2% during the fourth quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock worth $36,000 after buying an additional 33 shares during the last quarter. Finally, VSM Wealth Advisory LLC acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $36,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Up 1.9%

Shares of NYSE TMO traded up $7.95 during mid-day trading on Tuesday, reaching $426.65. The company had a trading volume of 2,620,440 shares, compared to its average volume of 1,982,484. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The stock has a market capitalization of $161.06 billion, a PE ratio of 25.02, a price-to-earnings-growth ratio of 2.23 and a beta of 0.77. The stock's 50 day moving average is $409.13 and its 200-day moving average is $478.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The business had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same period in the prior year, the business posted $5.11 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up .2% compared to the same quarter last year. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on TMO shares. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Evercore ISI decreased their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday. The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Royal Bank Of Canada decreased their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Finally, UBS Group lowered Thermo Fisher Scientific to a "neutral" rating in a research note on Tuesday. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average price target of $603.05.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.